Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study McMichael, A., Cork, M., Teng, J., Rojo, R., Valdez, H., Zhang, F., Myers, D., Chan, G., DiBonaventura, M. MOSBY-ELSEVIER. 2021: AB156

View details for Web of Science ID 000629158000501